At one time, a diagnosis of cancer was generally a death sentence for most patients. At the very least, it meant months of painful radiation treatments and chemotherapy. But today the treatment of cancer is evolving in ways that no one could have imagined just 20 years ago. Precision medicine is providing researchers with the ability to accurately match patients with the most effective treatment for their tumors. The resulting treatments, such as Merck’s KEYTRUDA, are now providing real hope to patients and allowing them to beat their cancers.
But what does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? I spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.